By Razak Musah Baba

LONDON--GlaxoSmithKline PLC (GSK.LN) said Thursday that the U.S. Food and Drug Administration has approved Flonase Allergy Relief as an over-the-counter treatment for temporary relief of the symptoms of hay fever or upper respiratory allergies.

The U.K. drug maker said Flonase Allergy Relief will be available over the counter in early 2015.

GlaxoSmithKline shares closed Thursday at GBP14.70, valuing the company at GBP71.25 billion.

Write to Razak Musah Baba at razak.baba@wsj.com; Twitter: @Raztweet

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Gsk (LSE:GSK)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Gsk Charts.
Gsk (LSE:GSK)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Gsk Charts.